EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Iloprost infusion reduces serological cytokines and hormones of hypoxia and inflammation in systemic sclerosis patients

Chiara Pellicano, Amalia Colalillo, Oriana De Marco, Valeria Carnazzo, Umberto Basile, Antonietta Gigante, Rosario Cianci, Edoardo Rosato

Clinical and Experimental Medicine · 2024

DOI: 10.1007/s10238-024-01374-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Medicine, 2024. Verfasst von Chiara Pellicano und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational and Precision Medicine, Sapienza University of Rome, Viale Dell'Università 37, 00185, Rome, Italy. Hauptthemen laut MEDLINE: Iloprost, Fibroblast Growth Factor-23, Scleroderma, Systemic, Fibroblast Growth Factors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Roma La Sapienza.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Systemic sclerosis (SSc) is characterized by microvascular damage of skin and internal organs with chronic hypoxia and release of cytokines and hormones such as neutrophil gelatinase-associated lipocalin (NGAL), fibroblast growth factor-23 (FGF-23) and Klotho. Aim of the study was to evaluate FGF-23, Klotho and NGAL serum levels in SSc patients and healthy controls (HC) and to evaluate serum levels changes of FGF-23, Klotho and NGAL after Iloprost.

Methods

Twenty-one SSc patients and 20 HC were enrolled. In SSc patients, peripheral venous blood samples were collected at the first day before the autumn Iloprost infusion (t0), 60 min (t1) and 14 days after Iloprost infusion (t2).

Results

SSc patients had higher serum level of FGF-23 [18.7 ± 6.4 pg/ml versus 3.6 ± 2.2 pg/ml, p < 0.001], Klotho [5.1 ± 0.8 pg/ml versus 2.3 ± 0.6 pg/ml, p < 0.001] and NGAL [20.9 ± 2.6 pg/ml versus 14.5 ± 1.7 pg/ml, p < 0.001] than HC. Iloprost infusion reduces serum level of FGF-23 (18.7 ± 6.4 pg/ml versus 10.4 ± 5.5 pg/ml, p < 0.001), Klotho (5.1 ± 0.8 pg/ml versus 2.5 ± 0.6 pg/ml, p < 0.001) and NGAL (20.9 ± 2.6 pg/ml versus 15.1 ± 2.3 pg/ml, p < 0.001) between t0 and t1. The Iloprost infusion reduces serum level of FGF-23 (18.7 ± 6.4 pg/ml versus 6.6 ± 5.1 pg/ml), Klotho (5.1 ± 0.8 pg/ml versus 2.3 ± 0.4 pg/ml) and NGAL (20.9 ± 2.6 pg/ml versus 15.5 ± 1.9 pg/ml) between t0 and t2.

Conclusions

SSc patients had higher FGF-23, Klotho and NGAL than HC. Iloprost reduces serum levels of FGF-23, Klotho and NGAL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IloprostFibroblast Growth Factor-23Scleroderma, SystemicFibroblast Growth FactorsLipocalin-2GlucuronidaseKlotho ProteinsHumansFemaleMiddle AgedMaleAdultCytokinesAgedHypoxiaInfusions, IntravenousInflammation

Stichwörter der Autor:innen

FGF-23HypoxiaKlothoNGALSystemic sclerosis

Substanzen

IloprostFibroblast Growth Factor-23FGF23 protein, humanFibroblast Growth FactorsLipocalin-2LCN2 protein, humanGlucuronidaseKlotho ProteinsCytokines

Autor:innen und Institutionen

  • Department of Translational and Precision Medicine, Sapienza University of Rome, Viale Dell'Università 37, 00185, Rome, Italy.
  • Department of Public Health, Nephrology Unit, University Federico II, 80138, Naples, Italy.
  • UOC of Clinical Pathology DEA II Level, Hospital Santa Maria Goretti-ASL Latina, 04100, Latina, Italy.
  • Department of Translational and Precision Medicine, Sapienza University of Rome, Viale Dell'Università 37, 00185, Rome, Italy. edoardo.rosato@uniroma1.it.

Förderung

  • Università degli Studi di Roma La Sapienza

Zitieren

APA

Pellicano, C., Colalillo, A., De Marco, O., Carnazzo, V., Basile, U., Gigante, A., Cianci, R., & Rosato, E. (2024). Iloprost infusion reduces serological cytokines and hormones of hypoxia and inflammation in systemic sclerosis patients. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-024-01374-4

Vancouver

Pellicano C, Colalillo A, De Marco O, Carnazzo V, Basile U, Gigante A, et al. Iloprost infusion reduces serological cytokines and hormones of hypoxia and inflammation in systemic sclerosis patients. Clinical and Experimental Medicine. 2024. doi:10.1007/s10238-024-01374-4

BibTeX
@article{Pellicano2024,
  author = {Pellicano, Chiara and Colalillo, Amalia and De Marco, Oriana and Carnazzo, Valeria and Basile, Umberto and Gigante, Antonietta and Cianci, Rosario and Rosato, Edoardo},
  title = {Iloprost infusion reduces serological cytokines and hormones of hypoxia and inflammation in systemic sclerosis patients},
  journal = {Clinical and Experimental Medicine},
  year = {2024},
  doi = {10.1007/s10238-024-01374-4}
}
Kostenlos starten →